iBio (IBIO) Liabilities and Shareholders Equity (2011 - 2026)

iBio (IBIO) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $85.8 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 349.32% year-over-year to $85.8 million in Q1 2026; TTM through Mar 2026 was $237.6 million, a 152.59% increase from a year earlier, with the FY2025 full-year figure at $23.2 million, down 19.31% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $85.8 million, up from $64.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IBIO reached as high as $115.4 million in Q1 2022 and fell as low as $19.1 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $52.4 million across 5 years, with a median of $44.4 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity plunged 61.91% in 2025 and surged 349.32% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $51.8 million in 2022, then plunged by 34.32% to $34.0 million in 2023, then sank by 36.23% to $21.7 million in 2024, then soared by 196.78% to $64.4 million in 2025, then jumped by 33.3% to $85.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $85.8 million in Q1 2026, $64.4 million in Q4 2025, and $64.2 million in Q3 2025.